LaCARP opens clinical trials to patients of all primary care providers.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000225:Adenine / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D004352:Drug Resistance, Microbial / Q000235:genetics*; D004359:Drug Therapy, Combination; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D008145:Louisiana; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D019888:Nelfinavir / Q000627:therapeutic use; D018579:Patient Selection; D019438:Ritonavir / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D017320:HIV Protease Inhibitors; D017963:Azithromycin; D019888:Nelfinavir; D000225:Adenine; D019438:Ritonavir